{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients with high-risk stage II or stage III nonmetastatic colorectal cancer who underwent curative-intended surgery were randomized to either 3 or 6 months of adjuvant chemotherapy."
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients with high-risk stage II or stage III nonmetastatic colorectal cancer who underwent curative-intended surgery."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients were grouped according to the start of adjuvant chemotherapy being less than 6 weeks vs greater than 6 weeks after surgery."
      },
      "Objective": {
        "score": 1,
        "evidence": "Objective: To analyze the association between the timing of adjuvant chemotherapy after surgery for colorectal cancer and disease-free survival."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary end point was disease-free survival."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 5719 patients (2251 [39.4%] female; mean [SD] age, 63.4 [9.3] years) were included in the primary analysis after data curation; among them, 914 were in the early-start group and 4805 were in the late-start group."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "A total of 5719 patients (2251 [39.4%] female; mean [SD] age, 63.4 [9.3] years) were included in the primary analysis after data curation."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Five-year disease-free survival was 78.0% (95% CI, 75.3%-80.8%) in the early-start group and 73.2% (95% CI, 72.0%-74.5%) in the late-start group."
      },
      "Harms": {
        "score": 1,
        "evidence": "In adjusted logistic regression models, there was no association with adverse events in the total treatment period (odds ratio, 0.82; 95% CI, 0.65-1.04; P =\u2009.09) or adverse events in the first cycle of treatment (odds ratio, 0.77; 95% CI, 0.56-1.09; P =\u2009.13)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration: isrctn.org Identifier: ISRCTN59757862"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 16,
    "max_score": 25
  },
  "model": "gpt-4o"
}